FOXO4-dri mastery course
Unit 7 of 11
Safety, Selectivity, and Evidence Limitations
What the selectivity data shows and what it does not.
the selectivity question
The central safety claim for FOXO4-DRI is that it selectively kills senescent cells while leaving normal cells unharmed. This unit examines the evidence supporting that claim, identifies the gaps in the data, and outlines the theoretical risks that have not yet been tested.
Selectivity Comparison Chart
Visualize how FOXO4-DRI selectivity compares across cell types and senescence states.
selectivity comparison chart
safety evidence at a glance
Key facts about FOXO4-dri selectivity and evidence gaps.
3 cell populations
baar et al. tested senescent, quiescent, and proliferating cells -- senescent cells showed highest sensitivity, proliferating cells the least
concentration-dependent
selectivity is dose-dependent, not absolute -- at higher concentrations normal cells also show viability reduction
no toxicology package
no published acute toxicity, repeat-dose toxicity, genotoxicity, or reproductive toxicity studies exist for FOXO4-dri
no human pk data
absorption, distribution, metabolism, and excretion data in humans does not exist -- bioavailability and elimination half-life are unknown
FOXO4-DRI has no human clinical trials. The risk profile in humans is genuinely unknown -- not merely understudied. No formal toxicology package has been published, and no human pharmacokinetic data exists. This is fundamentally different from compounds with published phase 1 safety data.
key terms
Definitions for this unit.
S
The ratio of IC50 for normal cells to IC50 for senescent cells. A higher ratio indicates greater selectivity for senescent cells. Baar et al. showed meaningful separation in viability curves but did not explicitly report this ratio.
T
Dangerous reduction in platelet count. Navitoclax causes this because platelets depend on BCL-XL for survival -- illustrating how unexpected normal cell types can be affected by senolytic mechanisms targeting survival pathways.
I
Standard preclinical studies required to support an investigational new drug application: acute toxicity, repeat-dose toxicity, genotoxicity, and reproductive toxicity. None of these have been published for FOXO4-DRI.
Q
Cells that have entered reversible growth arrest, typically by serum starvation. In Baar et al. selectivity experiments, quiescent cells showed substantially less sensitivity to FOXO4-DRI than senescent cells but were not completely resistant.
I
The potential for a therapeutic peptide to provoke an immune response. While DRI chemistry reduces proteasomal processing and MHC-I presentation, repeated dosing could generate neutralizing antibodies via B-cell or MHC-II pathways.